The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery
Sponsor: The University of Texas Health Science Center at San Antonio • ClinicalTrials.gov ID: NCT07212868
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The goal of this study is to understand the role of glucagon signal on glucose metabolism in individuals with and without bariatric surgery. The study is involved with measuring glucose metabolism with glucagon infusion and glucagon receptor blockade. We use an investigational drug called REMD 477. "Investigational" means that the has not yet been approved by the U.S. Food \& Drug Administration (FDA). REMD-477 is a monoclonal antibody (an antibody made by cloning a unique white blood cell) that blocks the effect of glucagon.
Interventions
-
REMD-477 versus Placebo
(Drug)
Placebo versus glucagon receptor antagonist using a human monoclonal antibody with a high level of antagonistic effect against human glucagon receptor.
-
Exogenous glucagon versus saline infusion
(Other)
The effect of increased glucagon concentrations in plasma on glucose metabolism during glucose clamp will be studied.
Eligibility criteria
Conditions
Locations
- Texas Diabetes Institute - University Health System — San Antonio, Texas, United States
- University of Texas San Antonio — San Antonio, Texas, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record